Publications

XENERA-1: a Randomised Double-Blind Phase Ii Trial of Xentuzumab in Combination with Everolimus and Exemestane Versus Everolimus and Exemestane in Patients with Hormone Receptor-Positive/Her2-Negative Metastatic Breast Cancer and Non-Visceral Disease

AuthID
P-00Y-MBE

Author(s)

Schmid, P

Cortes, J

Joaquim, A

Janez, NM

Morales, S

Diaz-Redondo, T

Blau, S

Neven, P

Lemieux, J

Garcia-Saenz, JA

Hart, L

Biyukov, T

Baktash, N

Massey, D

Burris, HA

Rugo, HS

Document Type

Article

Year published

2023

Published

in BREAST CANCER RESEARCH, ISSN: 1465-5411

Volume: 25, Issue: 1

Indexing

Wos^®

Scopus^®

Pubmed^®

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.1186/s13058-023-01649-w

Pubmed: 37308971

SCOPUS: 2-s2.0-85161871307

Wos: WOS:001012809300001

Source Identifiers

ISSN: 1465-5411

Export Publication Metadata

Marked List

Add to Marked List

Info

At this moment we don't have any links to full text documens.

XENERA-1: a Randomised Double-Blind Phase Ii Trial of Xentuzumab in Combination with Everolimus and Exemestane Versus Everolimus and Exemestane in Patients with Hormone Receptor-Positive/Her2-Negative Metastatic Breast Cancer and Non-Visceral Disease

Useful Links

Get Help

Federated Authentication (Click on the image)

XENERA-1: a Randomised Double-Blind Phase Ii Trial of Xentuzumab in Combination with Everolimus and Exemestane Versus Everolimus and Exemestane in Patients with Hormone Receptor-Positive/Her2-Negative Metastatic Breast Cancer and Non-Visceral Disease

Useful Links

Get Help